In particular, the Board has flagged products listed under Indian Pharmacopoeia, warning that they do not meet the country’s drug registration require...

In a statement on Wednesday, the PPB expressed concern that the unregistered and substandard version of this critical drug poses significant risks to...

The Board further advised all pharmacies, hospitals, and members of the public to immediately stop selling or purchasing the recalled batch.

The Board's Enquiries and Disciplinary Committee (EDC) had taken action against these practitioners.

The Board emphasised that it remains committed to protecting the health of the public.

Chief Executive Officer of PPB Fred Siyoi, warned that health products and technologies obtained outside of the regulated supply chain risk public and...

The stolen pharmaceuticals were found in unlicensed chemists, posing serious health risks to the public due to their unregulated handling and distribu...

Thirty-six individuals have been apprehended, with legal actions commenced against several others, including 7 in Nairobi, 19 in Central Kenya, and 10...

The affected batches were sold in six countries including Kenya, South Africa, Eswatini, Rwanda, Tanzania and Nigeria.

The victim was diagnosed with a liver disorder and provided a prescription.

Patients who had consumed the product, were advised to immediately seek medical attention from a qualified healthcare professional.

The operation aims to eliminate counterfeit pharmacists and illicit pharmaceutical outlets, prioritizing public health protection.